二甲双胍治疗乳腺癌的分子细胞机制及临床应用研究进展

The evolving of metformin in breast cancer treatment: from molecular & cellular mechanism to clinical application

糖尿病是乳腺癌发病的高危因素,并影响乳腺癌患者的预后。二甲双胍是糖尿病一线用药,越来越多的证据表明,其还能通过多种途径起到抗肿瘤作用。近年来,许多学者提出了二甲双胍在抑制乳腺肿瘤干细胞及逆转乳腺癌细胞耐药性等方面的新思路。此外,有学者新开发出一种药物工具来控制二甲双胍的释放。本文将对二甲双胍治疗乳腺癌分子细胞机制及临床应用研究进展进行阐述。

Diabetes is a high risk factor for breast cancer and affects the prognosis of breast cancer patients. The increasing evidence indicates that mefformin, a first-line oral hypoglycemic drug for the treatment of type 2 diabetes, has anti-tumor effects in a variety of pathways. In recent years, many studies have put forward metformin＇s role in inhibiting breast cancer stem cells and resensitizing multiple drug resistant breast cancer cell lines. Besides, a study has developed a pharmacological tool to control the release of metformin. In this review, we aim to describe the new molecular cell mechanism of metformin in the treatment of breast cancer and the progress of clinical application.